Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

Luke Grundy, Andrea M Harrington, Joel Castro, Sonia Garcia-Caraballo, Annemie Deiteren, Jessica Maddern, Grigori Y Rychkov, Pei Ge, Stefanie Peters, Robert Feil, Paul Miller, Andre Ghetti, Gerhard Hannig, Caroline B Kurtz, Inmaculada Silos-Santiago, Stuart M Brierley

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.

LanguageEnglish
JournalJCI Insight
Volume3
Issue number19
DOIs
Publication statusE-pub ahead of print - 4 Oct 2018

Keywords

  • Journal Article

Cite this

Grundy, Luke ; Harrington, Andrea M ; Castro, Joel ; Garcia-Caraballo, Sonia ; Deiteren, Annemie ; Maddern, Jessica ; Rychkov, Grigori Y ; Ge, Pei ; Peters, Stefanie ; Feil, Robert ; Miller, Paul ; Ghetti, Andre ; Hannig, Gerhard ; Kurtz, Caroline B ; Silos-Santiago, Inmaculada ; Brierley, Stuart M. / Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction. In: JCI Insight. 2018 ; Vol. 3, No. 19.
@article{af10c19137cb4e9b94b49b734858444a,
title = "Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction",
abstract = "Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.",
keywords = "Journal Article",
author = "Luke Grundy and Harrington, {Andrea M} and Joel Castro and Sonia Garcia-Caraballo and Annemie Deiteren and Jessica Maddern and Rychkov, {Grigori Y} and Pei Ge and Stefanie Peters and Robert Feil and Paul Miller and Andre Ghetti and Gerhard Hannig and Kurtz, {Caroline B} and Inmaculada Silos-Santiago and Brierley, {Stuart M}",
year = "2018",
month = "10",
day = "4",
doi = "10.1172/jci.insight.121841",
language = "English",
volume = "3",
journal = "JCI Insight",
issn = "2379-3708",
number = "19",

}

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction. / Grundy, Luke; Harrington, Andrea M; Castro, Joel; Garcia-Caraballo, Sonia; Deiteren, Annemie; Maddern, Jessica; Rychkov, Grigori Y; Ge, Pei; Peters, Stefanie; Feil, Robert; Miller, Paul; Ghetti, Andre; Hannig, Gerhard; Kurtz, Caroline B; Silos-Santiago, Inmaculada; Brierley, Stuart M.

In: JCI Insight, Vol. 3, No. 19, 04.10.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

AU - Grundy, Luke

AU - Harrington, Andrea M

AU - Castro, Joel

AU - Garcia-Caraballo, Sonia

AU - Deiteren, Annemie

AU - Maddern, Jessica

AU - Rychkov, Grigori Y

AU - Ge, Pei

AU - Peters, Stefanie

AU - Feil, Robert

AU - Miller, Paul

AU - Ghetti, Andre

AU - Hannig, Gerhard

AU - Kurtz, Caroline B

AU - Silos-Santiago, Inmaculada

AU - Brierley, Stuart M

PY - 2018/10/4

Y1 - 2018/10/4

N2 - Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.

AB - Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.

KW - Journal Article

U2 - 10.1172/jci.insight.121841

DO - 10.1172/jci.insight.121841

M3 - Article

VL - 3

JO - JCI Insight

T2 - JCI Insight

JF - JCI Insight

SN - 2379-3708

IS - 19

ER -